vs
Side-by-side financial comparison of Aditxt, Inc. (ADTX) and ORGANIGRAM GLOBAL INC. (OGI). Click either name above to swap in a different company.
Aditxt, Inc. is the larger business by last-quarter revenue ($44.3K vs $39.6K, roughly 1.1× ORGANIGRAM GLOBAL INC.). ORGANIGRAM GLOBAL INC. runs the higher net margin — -192.9% vs -17051.3%, a 16858.4% gap on every dollar of revenue.
Aditxt, Inc. is a clinical-stage biotechnology company focused on immunology. It develops targeted therapies to promote immune tolerance for patients with autoimmune diseases and organ transplant recipients, plus immune monitoring technologies. Its main markets are in North America, with expansion efforts underway in other global developed healthcare regions.
Organigram Global Inc. is a leading Canadian producer of high-quality recreational and medical cannabis products. It offers a diverse portfolio of dried flower, edibles, vape products and pre-rolls, primarily serving the domestic Canadian market while expanding operations in select international markets including parts of Europe.
ADTX vs OGI — Head-to-Head
Income Statement — Q2 FY2024 vs Q3 FY2022
| Metric | | |
|---|---|---|
| Revenue | $44.3K | $39.6K |
| Net Profit | $-7.5M | $-76.5K |
| Gross Margin | 47.8% | — |
| Operating Margin | -13497.1% | -128.4% |
| Net Margin | -17051.3% | -192.9% |
| Revenue YoY | -80.0% | — |
| Net Profit YoY | -32.9% | — |
| EPS (diluted) | $-1047.17 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 24 | $44.3K | — | ||
| Q1 24 | $79.7K | — | ||
| Q4 23 | $81.3K | — | ||
| Q3 23 | $124.5K | — | ||
| Q2 23 | $221.0K | — | ||
| Q1 23 | $218.4K | — | ||
| Q4 22 | $185.6K | — | ||
| Q3 22 | $323.1K | — |
| Q2 24 | $-7.5M | — | ||
| Q1 24 | $-14.7M | — | ||
| Q4 23 | $-11.1M | — | ||
| Q3 23 | $-9.9M | — | ||
| Q2 23 | $-5.7M | — | ||
| Q1 23 | $-6.0M | — | ||
| Q4 22 | $-8.2M | — | ||
| Q3 22 | $-7.6M | — |
| Q2 24 | 47.8% | — | ||
| Q1 24 | 17.4% | — | ||
| Q4 23 | -251.6% | — | ||
| Q3 23 | 14.1% | — | ||
| Q2 23 | 15.9% | — | ||
| Q1 23 | 18.4% | — | ||
| Q4 22 | 8.3% | — | ||
| Q3 22 | 27.7% | — |
| Q2 24 | -13497.1% | — | ||
| Q1 24 | -14477.5% | — | ||
| Q4 23 | -9780.0% | — | ||
| Q3 23 | -6502.9% | — | ||
| Q2 23 | -1916.2% | — | ||
| Q1 23 | -2647.2% | — | ||
| Q4 22 | -4418.2% | — | ||
| Q3 22 | -1668.8% | — |
| Q2 24 | -17051.3% | — | ||
| Q1 24 | -18486.1% | — | ||
| Q4 23 | -13679.4% | — | ||
| Q3 23 | -7963.2% | — | ||
| Q2 23 | -2571.3% | — | ||
| Q1 23 | -2740.1% | — | ||
| Q4 22 | -4409.1% | — | ||
| Q3 22 | -2338.9% | — |
| Q2 24 | $-1047.17 | — | ||
| Q1 24 | $-91439.43 | — | ||
| Q4 23 | $-24998.07 | — | ||
| Q3 23 | $-1950.94 | — | ||
| Q2 23 | $-36.79 | — | ||
| Q1 23 | $-52.46 | — | ||
| Q4 22 | $-371.45 | — | ||
| Q3 22 | $-210.93 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $91.2K | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $6.6M | — |
| Total Assets | $28.4M | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 24 | $91.2K | — | ||
| Q1 24 | $88.7K | — | ||
| Q4 23 | $97.1K | — | ||
| Q3 23 | $1.7M | — | ||
| Q2 23 | $96.0K | — | ||
| Q1 23 | $302.5K | — | ||
| Q4 22 | $2.8M | — | ||
| Q3 22 | $9.2M | — |
| Q2 24 | $6.6M | — | ||
| Q1 24 | $9.9M | — | ||
| Q4 23 | $16.1M | — | ||
| Q3 23 | $-4.2M | — | ||
| Q2 23 | $-3.9M | — | ||
| Q1 23 | $68.1K | — | ||
| Q4 22 | $5.2M | — | ||
| Q3 22 | $12.7M | — |
| Q2 24 | $28.4M | — | ||
| Q1 24 | $28.0M | — | ||
| Q4 23 | $44.6M | — | ||
| Q3 23 | $8.2M | — | ||
| Q2 23 | $7.3M | — | ||
| Q1 23 | $7.6M | — | ||
| Q4 22 | $10.7M | — | ||
| Q3 22 | $19.2M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.3M | $-15.2K |
| Free Cash FlowOCF − Capex | — | $-19.9K |
| FCF MarginFCF / Revenue | — | -50.2% |
| Capex IntensityCapex / Revenue | — | 11.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 24 | $-2.3M | — | ||
| Q1 24 | $-6.0M | — | ||
| Q4 23 | $-3.9M | — | ||
| Q3 23 | $-8.0M | — | ||
| Q2 23 | $-3.3M | — | ||
| Q1 23 | $-4.0M | — | ||
| Q4 22 | $-6.7M | — | ||
| Q3 22 | $-7.8M | — |
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | $-8.0M | — | ||
| Q2 23 | $-3.3M | — | ||
| Q1 23 | $-4.0M | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — |
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | -6461.2% | — | ||
| Q2 23 | -1485.1% | — | ||
| Q1 23 | -1811.6% | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — |
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | 0.0% | — | ||
| Q3 23 | 7.5% | — | ||
| Q2 23 | 0.0% | — | ||
| Q1 23 | 2.3% | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADTX
Segment breakdown not available.
OGI
| Unrealized gain on changes in fair value of biological assets (Note 7) | $20.1K | 51% |
| Other | $19.6K | 49% |
